The Avastin Conspiracy

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.


Over at RedState, Brian Darling argues that the Food and Drug Administration’s decision to revoke its approval of the drug Avastin for use in late-stage breast cancer patients amounts to dreaded health care “rationing” brought on by (what else?) “Obamacare.” Darling isn’t alone in his pro-Avastin crusade—the Wall Street Journal editorial board has been harping on this, too. They’re both wrong. Avik Roy, a right-wing policy writer, did a good job of explaining why last month:

The panel’s new recommendation came on the heels of new data showing that Avastin did not extend the survival of patients with advanced breast cancer. (In cancer trials, the length of a patient’s life on a given treatment is the accepted gold standard for measuring a treatment’s effectiveness.) In the Avastin trial, called AVADO, patients treated with placebo and Taxotere, another cancer drug, lived for 31.9 months on average; whereas patients treated with Avastin and Taxotere lived for 30.8 months at a low Avastin dose and 30.2 months at a high Avastin dose. Understandably, the FDA’s advisory committee saw this data as evidence that Avastin didn’t offer a real benefit to breast cancer patients.

[…]

[W]e can’t forget that one of Avastin’s principal side effects is financial: a year’s worth of the drug costs between $80,000 and $100,000.

The real problem is this: if the government is responsible for paying for our health care, the government is entitled, if not obligated, to decide how to spend its money most effectively. If we don’t want the government to be making these decisions for us, then we need to pay for our own medicines. We can’t have it both ways.

I know RedStaters may not believe the “liberal media” when it reports that Avastin is an incredibly expensive drug that doesn’t work particularly well on late-stage breast cancer. But maybe they’ll believe Roy, who also writes for the National Review. Read the whole thing.

TIME IS RUNNING OUT!

We have an ambitious $350,000 online fundraising goal this month and it's truly crunch time: About 15 percent of our yearly online giving usually comes in during the final week of the year, and in "No Cute Headlines or Manipulative BS," we explain why we simply can't afford to come up short right now.

The bottom line: Corporations and powerful people with deep pockets will never sustain the type of journalism Mother Jones exists to do. And advertising or profit-driven ownership groups will never make time-intensive, in-depth reporting viable.

That's why donations big and small make up 74 percent of our budget this year. There is no backup to keep us going, no alternate revenue source, no secret benefactor. If readers don’t donate, we won’t be here. It's that simple.

And if you can help us out with a donation right now, all online gifts will be matched thanks to an incredibly generous matching gift pledge.

payment methods

TIME IS RUNNING OUT!

We have an ambitious $350,000 online fundraising goal this month and it's truly crunch time: About 15 percent of our yearly online giving usually comes in during the final week of the year, and in "No Cute Headlines or Manipulative BS," we explain why we simply can't afford to come up short right now.

The bottom line: Corporations and powerful people with deep pockets will never sustain the type of journalism Mother Jones exists to do. And advertising or profit-driven ownership groups will never make time-intensive, in-depth reporting viable.

That's why donations big and small make up 74 percent of our budget this year. There is no backup to keep us going, no alternate revenue source, no secret benefactor. If readers don’t donate, we won’t be here. It's that simple.

And if you can help us out with a donation right now, all online gifts will be matched thanks to an incredibly generous matching gift pledge.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate